Freenome recently announced that it has appointed diagnostics industry veteran Aaron Elliott as its new CEO. Elliott succeeds Mike Nolan, who resigned on 25 September 2024 for personal reasons, and takes over from Freenome’s co-founder Riley Ennis, who led the liquid biopsy company during the transition period.
Elliott spent nearly 20 years in the diagnostics space. Most recently, he was president and CEO at REALM IDx, Inc. where he oversaw its subsidiaries Ambry Genetics, Invicro and Konica...
Key Takeaways
- Freenome appointed Aaron Elliott as CEO who previously held leadership roles at REALM IDx and Ambry Genetics.
- Elliott’s priorities will be on...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?